Freedom of Information Request: 0372 2019/20

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)? 22
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?

• Locally advanced 2
• Recurrent metastatic 0
• Unknown 0

3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

• Carboplatin (only or in combination with 5-FU) – 3
• Cisplatin (only or in combination with 5-FU) – 5
• Cetuximab with/without chemotherapy – 2
• Cetuximab with radiotherapy – 0
• Pembrolizumab monotherapy – 0
• Pembrolizumab with chemotherapy – 0
• Nivolumab –  4
• Docetaxel (only or in combination with 5-FU) – 0
• Fluorouracil (5FU) – 0
• Radiotherapy only – 9
• Other

4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

• Aflibercept – 0
• Bevacizumab – 0
• Capecitabine – 14
• CAPIRI – 0
• CAPOX – 32
• Cetuximab not in combination with FOLFIRI or FOLFOX – 0
• Cetuximab in combination with FOLFIRI – 13
• Cetuximab in combination with FOLFOX – 3
• Irinotecan – 5
• FOLFIRI – 32
• FOLFOX – 33
• Oxaliplatin – 3
• Panitumumab not in combination with FOLFIRI or FOLFOX – 0
• Panitumumab in combination with FOLFIRI – 1
• Panitumumab in combination with FOLFOX – 0
• Nivolumab – 2
• Raltitrexed – 2
• Ramucirumab – 0
• Regorafenib – 0
• Sorafenib – 0
• 5FU only – 91
• Tegafur Uracil + 5FU – 0
• Trifluridine–tipiracil – 0
• XELOX – 31
• Other – 55